Abbott Laboratories (ABT) Cash & Current Investments (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Cash & Current Investments data on file, last reported at $7.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 6.59% year-over-year to $7.3 billion; the trailing twelve-month figure through Mar 2026 stood at $7.3 billion (up 6.59% YoY), and the FY2025 full-year result was $8.9 billion, up 12.2% from the prior year.
• Cash & Current Investments fell to $7.3 billion in Q1 2026, from $8.9 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $10.2 billion in Q4 2022 to a low of $6.7 billion in Q1 2024.
• A 5-year average of $8.1 billion and a median of $7.8 billion in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments gained 16.84% in 2023 and plunged 30.22% in 2024, its largest moves.
• Tracing ABT's Cash & Current Investments over 5 years: stood at $10.2 billion in 2022, then dropped by 28.43% to $7.3 billion in 2023, then rose by 9.45% to $8.0 billion in 2024, then grew by 12.2% to $8.9 billion in 2025, then dropped by 18.39% to $7.3 billion in 2026.
• Business Quant data shows ABT's Cash & Current Investments at $7.3 billion in Q1 2026, $8.9 billion in Q4 2025, and $7.7 billion in Q3 2025.